Allspring Global Investments Holdings LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 12.2% in the fourth quarter, Holdings Channel reports. The firm owned 15,368 shares of ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...

近日， Moderna（NASDAQ: MRNA) 股价因剧烈波动触发了盘中熔断，这一事件在市场上掀起了巨大的波澜。根据港股那点事的报道，消息面上，Moderna因美国食品药品监督管理局（FDA）对其诺如病毒疫苗试验的暂停作出响应。根据Moderna的声明，该公司预计这一暂停决定对其诺如病毒疫苗的试验进度影响甚微。然而，市场的反应却并不平静。

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) shares were down 7.9% on Thursday after UBS Group lowered their price target on the stock from $96.00 to $78.00.UBS Group currently has a buy rating ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...

Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other hand, the company’s full-year ...